Is Aptevo Therapeutics Stock a Good Investment?
Aptevo Therapeutics Investment Advice | APVO |
- Examine Aptevo Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Aptevo Therapeutics' leadership team and their track record. Good management can help Aptevo Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Aptevo Therapeutics' business and its evolving consumer preferences.
- Compare Aptevo Therapeutics' performance and market position to its competitors. Analyze how Aptevo Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Aptevo Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Aptevo Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Aptevo Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Aptevo Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Aptevo Therapeutics Stock
Researching Aptevo Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company has price-to-book (P/B) ratio of 0.79. Some equities with similar Price to Book (P/B) outperform the market in the long run. Aptevo Therapeutics recorded a loss per share of 87.38. The entity last dividend was issued on the 27th of March 2020. The firm had 1:37 split on the 4th of December 2024.
To determine if Aptevo Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Aptevo Therapeutics' research are outlined below:
| Aptevo Therapeutics generated a negative expected return over the last 90 days | |
| Aptevo Therapeutics has high historical volatility and very poor performance | |
| Aptevo Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (24.13 M) with loss before overhead, payroll, taxes, and interest of (302 K). | |
| Aptevo Therapeutics currently holds about 29.43 M in cash with (23.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.78, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from finance.yahoo.com: RAINIER Trial Data Update Two Additional AML Patients Achieve Remission Within 30 Days of Treatment |
Aptevo Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Aptevo Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Aptevo Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Aptevo Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Aptevo Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-11-14 | 2023-09-30 | -0.75 | -0.5 | 0.25 | 33 | ||
2021-08-12 | 2021-06-30 | -2 | -1.75 | 0.25 | 12 | ||
2022-05-12 | 2022-03-31 | -1.15 | -1.55 | -0.4 | 34 | ||
2020-05-13 | 2020-03-31 | -2.35 | -2.84 | -0.49 | 20 | ||
2023-03-30 | 2022-12-31 | -1.53 | -0.95 | 0.58 | 37 | ||
2021-03-31 | 2020-12-31 | -1.22 | -1.92 | -0.7 | 57 | ||
2018-08-09 | 2018-06-30 | -9.03 | -8.12 | 0.91 | 10 | ||
2018-05-10 | 2018-03-31 | -7.77 | -8.82 | -1.05 | 13 |
Know Aptevo Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Aptevo Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Aptevo Therapeutics backward and forwards among themselves. Aptevo Therapeutics' institutional investor refers to the entity that pools money to purchase Aptevo Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bank Of America Corp | 2024-12-31 | 4.0 | Truvestments Capital Llc | 2024-09-30 | 2.0 | Jane Street Group Llc | 2024-12-31 | 0.0 | Wells Fargo & Co | 2024-12-31 | 0.0 | Northern Trust Investments N A | 2024-12-31 | 0.0 | Citadel Advisors Llc | 2024-12-31 | 0.0 | Two Sigma Investments Llc | 2024-12-31 | 0.0 | Sabby Management Llc | 2024-09-30 | 0.0 | Hudson Bay Capital Management Lp | 2024-12-31 | 0.0 | Virtu Financial Llc | 2024-12-31 | 21.6 K | Hrt Financial Llc | 2024-12-31 | 12.3 K |
Aptevo Therapeutics' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.75 M.Market Cap |
|
Aptevo Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.55) | (1.47) | |
| Return On Capital Employed | (2.62) | (2.75) | |
| Return On Assets | (1.55) | (1.47) | |
| Return On Equity | (5.07) | (5.33) |
Determining Aptevo Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Aptevo Therapeutics is a good buy. For example, gross profit margin measures Aptevo Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Aptevo Therapeutics' profitability and make more informed investment decisions.
Evaluate Aptevo Therapeutics' management efficiency
Aptevo Therapeutics has return on total asset (ROA) of (0.7606) % which means that it has lost $0.7606 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.8428) %, meaning that it created substantial loss on money invested by shareholders. Aptevo Therapeutics' management efficiency ratios could be used to measure how well Aptevo Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of March 2025, Return On Tangible Assets is likely to grow to -1.47. In addition to that, Return On Capital Employed is likely to drop to -2.75. At this time, Aptevo Therapeutics' Net Tangible Assets are very stable compared to the past year. As of the 24th of March 2025, Other Current Assets is likely to grow to about 2.9 M, while Total Assets are likely to drop about 14.8 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 16.68 | 15.85 | |
| Tangible Book Value Per Share | 16.68 | 15.85 | |
| Enterprise Value Over EBITDA | 0.12 | 0.12 | |
| Price Book Value Ratio | 0.26 | 0.25 | |
| Enterprise Value Multiple | 0.12 | 0.12 | |
| Price Fair Value | 0.26 | 0.25 | |
| Enterprise Value | 81 M | 76.9 M |
The leadership approach at Aptevo Therapeutics' fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Beta 5.237 |
Basic technical analysis of Aptevo Stock
As of the 24th of March, Aptevo Therapeutics shows the Standard Deviation of 5.23, mean deviation of 3.94, and Risk Adjusted Performance of (0.09). Aptevo Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Aptevo Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aptevo Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aptevo Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Aptevo Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Aptevo Therapeutics' Outstanding Corporate Bonds
Aptevo Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Aptevo Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Aptevo bonds can be classified according to their maturity, which is the date when Aptevo Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| US03835VAH96 Corp BondUS03835VAH96 | View | |
| Aptiv 435 percent Corp BondUS03835VAG14 | View | |
| APTIV PLC 44 Corp BondUS03835VAF31 | View | |
| APTV 31 01 DEC 51 Corp BondUS03835VAJ52 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| ATR 36 15 MAR 32 Corp BondUS038336AA11 | View |
Understand Aptevo Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Aptevo Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | (0.79) | |||
| Mean Deviation | 3.94 | |||
| Coefficient Of Variation | (926.84) | |||
| Standard Deviation | 5.23 | |||
| Variance | 27.32 | |||
| Information Ratio | (0.1) | |||
| Jensen Alpha | (0.53) | |||
| Total Risk Alpha | (0.18) | |||
| Treynor Ratio | (0.80) | |||
| Maximum Drawdown | 30.46 | |||
| Value At Risk | (7.49) | |||
| Potential Upside | 8.25 | |||
| Skewness | (0.33) | |||
| Kurtosis | 1.44 |
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | (0.79) | |||
| Mean Deviation | 3.94 | |||
| Coefficient Of Variation | (926.84) | |||
| Standard Deviation | 5.23 | |||
| Variance | 27.32 | |||
| Information Ratio | (0.1) | |||
| Jensen Alpha | (0.53) | |||
| Total Risk Alpha | (0.18) | |||
| Treynor Ratio | (0.80) | |||
| Maximum Drawdown | 30.46 | |||
| Value At Risk | (7.49) | |||
| Potential Upside | 8.25 | |||
| Skewness | (0.33) | |||
| Kurtosis | 1.44 |
Consider Aptevo Therapeutics' intraday indicators
Aptevo Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Aptevo Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Aptevo Therapeutics Corporate Filings
8K | 20th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 4th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
S1 | 3rd of March 2025 Report filed by companies planning on going public to register their securities with the U.S. Securities and Exchange Commission (SEC) | ViewVerify |
| 10th of February 2025 Other Reports | ViewVerify |
Aptevo Stock media impact
Far too much social signal, news, headlines, and media speculation about Aptevo Therapeutics that are available to investors today. That information is available publicly through Aptevo media outlets and privately through word of mouth or via Aptevo internal channels. However, regardless of the origin, that massive amount of Aptevo data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Aptevo Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Aptevo Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Aptevo Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Aptevo Therapeutics alpha.
Aptevo Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Aptevo Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Aptevo Therapeutics Corporate Executives
Elected by the shareholders, the Aptevo Therapeutics' board of directors comprises two types of representatives: Aptevo Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aptevo. The board's role is to monitor Aptevo Therapeutics' management team and ensure that shareholders' interests are well served. Aptevo Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aptevo Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daphne Taylor | Senior CFO | Profile | |
| Daphne CPA | Senior CFO | Profile | |
| Jeffrey CA | Executive COO | Profile |
Already Invested in Aptevo Therapeutics?
The danger of trading Aptevo Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Aptevo Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Aptevo Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Aptevo Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Aptevo Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aptevo Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aptevo Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aptevo Therapeutics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptevo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Aptevo Stock, please use our How to Invest in Aptevo Therapeutics guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptevo Therapeutics. If investors know Aptevo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptevo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Aptevo Therapeutics is measured differently than its book value, which is the value of Aptevo that is recorded on the company's balance sheet. Investors also form their own opinion of Aptevo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aptevo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptevo Therapeutics' market value can be influenced by many factors that don't directly affect Aptevo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Aptevo Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Aptevo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptevo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.